Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.
Nosaki K, Yoh K, Toyozawa R, Horinouchi H, Morise M, Ohashi K, Murakami H, Satouchi M, Sakakibara-Konishi J, Yano S, Okumura F, Matsumoto S, Shimokawa M, Seto T, Goto K.
Nosaki K, et al. Among authors: seto t.
Int J Clin Oncol. 2024 May 17. doi: 10.1007/s10147-024-02543-x. Online ahead of print.
Int J Clin Oncol. 2024.
PMID: 38758397